(Q44169635)

30 November 2017

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. (English)

1 reference

30 November 2017

0 references

1 reference

1 reference

15

D Gray Heppner

1 reference

30 November 2017

V Ann Stewart

1

1 reference

30 November 2017

Shannon M McGrath

2

1 reference

30 November 2017

Douglas S Walsh

3

1 reference

30 November 2017

Stacey Davis

4

1 reference

30 November 2017

Aaron S Hess

5

1 reference

30 November 2017

Lisa A Ware

6

1 reference

30 November 2017

Kent E Kester

7

1 reference

30 November 2017

James F Cummings

8

1 reference

30 November 2017

J Robert Burge

9

1 reference

30 November 2017

Gerald Voss

10

1 reference

30 November 2017

Martine Delchambre

11

1 reference

30 November 2017

Nathalie Garçon

12

1 reference

30 November 2017

Douglas B Tang

13

1 reference

30 November 2017

Joe D Cohen

14

1 reference

30 November 2017

language of work or name

English

0 references

publication date

3 July 2006

1 reference

30 November 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

30 November 2017

24

1 reference

30 November 2017

42-43

1 reference

30 November 2017

6483-6492

1 reference

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

The economic and social burden of malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Epidemiology of drug-resistant malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Balancing risks on the backs of the poor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Malaria vaccines in development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Evolutionary stability of transspecies major histocompatibility complex class II DRB lineages in humans and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Evolution of the class II major histocompatibility complex alleles in higher primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Assay, purification and characterization of a recombinant malaria circumsporozoite fusion protein by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Evaluation of Elispot assays: influence of method and operator on variability of results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

Immune effector mechanisms in malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.033

10.1016/J.VACCINE.2006.06.033

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference